ScripCidara Therapeutics’ business outlook improved substantially on June 23 after releasing pre-market Phase IIb data for its non-vaccine seasonal influenza prevention agent showing better prophylaxis cap
ScripScrip regularly covers business development and deal making in the biopharmaceutical industry. Asia Deal Watch is supported by deal intelligence from Biomedtracker. SunRock, Escugen Partner To Develo
ScripGilead Sciences has obtained US approval for its HIV-1 capsid inhibitor, lenacapavir, as a twice-yearly subcutaneous injection to prevent HIV infection – an endorsement that should secure the product